MoreNews

  • Monday, September 26, 2022
    The Food and Drug Administration (FDA) has approved Omlonti® (omidenepag isopropyl ophthalmic solution) 0.002% for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Omlonti is a relatively selective prostaglandin E2 (EP2) receptor agonist designed to increase aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways. The approval was based on data from 3 randomized controlled clinical trials in patients with open-angle glaucoma or ocular hypertension with an average baseline IOP of 24 to 26mmHg.The double-masked treatment duration was 3 months in all 3 studies. The third study included a 9-month open-label ...
  • Monday, August 22, 2022
    After examining national survey data, researchers found a bidirectional association in patients with cataracts and with asthma.Cataracts are the leading cause of preventable blindness and the main cause of visual impairment[1] on a global scale, which makes learning the ways it can develop an important matter of public health.Asthma[2], too, is also a global public health problem. Whether there is a relationship between the 2 diseases was the aim of a recent study published in BMC Ophthalmology[3], which found that patients with asthma were more likely to develop cataracts than patients without, as well as the other way around.This study ...